(Q36027452)

11 August 2017

The effect of adjuvant cyclophosphamide or tamoxifen on the numbers of lymphocytes bearing T cell or NK cell markers (English)

1 reference

11 August 2017

1 reference

Sheard CR

1

1 reference

11 August 2017

Reilly F

2

1 reference

11 August 2017

Tee DE

3

1 reference

11 August 2017

Vergani D

4

1 reference

11 August 2017

Lowe D

5

1 reference

11 August 2017

Baum M

6

1 reference

11 August 2017

Cameron AE

7

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 October 1986

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

54

1 reference

11 August 2017

4

1 reference

11 August 2017

705-709

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1986.230

11 August 2017

0 references

cites work

T lymphocyte subsets in the peripheral blood of patients with benign and malignant breast disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001508

Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001508

In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001508

Altered helper and suppressor lymphocyte populations in surgical patients. A measure of postoperative immunosuppression.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001508

Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001508

The relationship of clinical status and therapeutic modality to natural killer cell activity in human breast cancer.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2001508

Augmentation of the human immune response by cyclophosphamide

23 September 2018

1 reference

12 December 2020

Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes

1 reference

12 December 2020

Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide

1 reference

12 December 2020

Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1986.230

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

3490874

1 reference